BoBNCT03767075
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
At risk: Primary completion moved at least 1 year 11 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 8 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from May 2025 to May 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 51 words
- Study completion pushed from Nov 2026 to Nov 2027
- Study description shortened, about 9 words
- Site details revised at 2 of 8 sites
Notable Eligibility criteria expanded, about 814 wordsv8 Show 7 more changesShow less
- Primary endpoint revised
- Study sites: 6 to 8
- Interventions: Arm 1 - atezolizumab (Drug) to Amivantamab (Drug), Atezolizumab (Drug), Futibatinib (Drug)
- Secondary endpoints: 3 to 5
- Study description expanded, about 255 words
- Collaborators: 2 to 4
- Study arms: 1 to 3
- Notable Primary completion date: May 2022 to May 2025
- Study completion date: Nov 2022 to Nov 2026
- Notable Primary completion date: May 2021 to May 2022
- Study completion date: Nov 2021 to Nov 2022
- Minor Study sites: 5 to 6
- Primary completion date: Jan 2021 to May 2021
- Study completion date: Jul 2021 to Nov 2021
Show 2 earlier versionsHide 2 earlier versions
- Minor Study sites: 3 to 5v3
- Minor Study sites: 2 to 3
- Start date changed from estimate of Dec 5, 2018 to Dec 10, 2018
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
Genomically selected populations will all receive the same drug * Arm 1A: BRCA1 or BRCA2 mutations * Arm 1B: MLH1, MSH2, MSH6, or PMS2 mutations * Arm 1C: tumors with POLE mutation, POLD1 mutation * Arm 1D: hypermutated tumors * Arm 1E: tumors with other mutations in DNA-repair genes * Arm 1F: tumors with amplified PDL1 * Arm 1G: tumours with CDK12 mutations Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 1000 subjects will need to be screened in part A in order to enroll 120 patients in part B of module 1.
Genomically selected populations will all receive the same drug * Arm 2A: Known pathogenic FGFR1-3 mutations * Arm 2B: Variants of unknown significance in FGFR1-3 with functional relevance or pathogenic FGFR4 mutations. * Arm 2C: Highly amplified FGFR1-3 with high FGFR1-3 mRNA (with the exception of gastric and breast cancer) * Arm 2D: Highly amplifiedFGFR1-3 without high FGFR1-3 mRNA (with the exception of gastric and breast cancer) Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 2000 subjects will need to be screened in part A in order to enroll 80 patients in part B of module 2.
Genomically selected populations will all receive the same drug * Arm 3A: kinase domain mutations/ MET fusion-genes (including intragene exon skipping MET-MET fusions) * Arm 3B: MET copy number gain (equivalent CNG ≥6) (exception: colorectal cancer) * Arm 3C: EGFR mutations (exception: primary lung malignancies) Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 1725 subjects will need to be screened in part A in order to enroll 69 patients in part B of module 3.
Drugs: Atezolizumab, Futibatinib, Amivantamab
Sites
8 sites in 7 countries
Germany 2, France 1, Italy 1, Netherlands 1, Spain 1, Sweden 1, United Kingdom 1